Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Executive Vice President & Phone: 332-895-3222 Chief Financial Officer investors@artivion.com Phone: 770-419-3355 Lance A. Berry Brian Johnston / Laine Morgan "The second quarter was exceptionally strong as we made progress across each of our strategic initiatives while delivering 14% constant currency revenue growth. Revenue growth was driven by year-over-year growth in On- X of 24%, stent grafts of 24%, BioGlue of 4%, and Preservati ...

Exhibit 99.1 Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress SAN DIEGO, CA, Aug 7, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported second quarter financial results and highlighted recent pipeline and business progress. "We continue ...

Exhibit 99.1 Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Shelton, Conn., August 7, 2025 – Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces second quarter ...

Expanded Contracts and Increased Fire Activity Drive Record Revenue and Earnings BELGRADE, Mont., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. ("Bridger", "the Company" or "Bridger Aerospace"), (NASDAQ: BAER, BAERW), one of the nation's largest aerial firefighting companies, today reported record results for the second quarter ended June 30, 2025. Second Quarter Highlights: | (in thousands) | For the three months ended | | | | For the six months ended | | | | --- | --- | --- | -- ...

"This quarter, continued progress across our strategic partnerships has further validated the strength and versatility of our Azymetric platform as well as our strategic partnership model, which enables broad and accelerated clinical development with the right collaborators. The achievement of key development milestones from these partnerships not only reinforces our scientific approach but also generated meaningful revenue, helping to offset our measured R&D cash burn," said Kenneth Galbraith, Chair and Ch ...

CompoSecure Reports Record Second Quarter 2025 Financial Results SOMERSET, N.J., August 7, 2025 -- CompoSecure, Inc. (Nasdaq: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced its financial and operating results for the second quarter ended June 30, 2025. "Our strong second quarter was driven by accelerating sales and improved profitability," said Jon Wilk, President and CEO of CompoSecure. "We achieved record results, fueled by robust domestic demand and growth ...

HEI Exhibit 99 "Our core operations performed as expected in the second quarter, with the utility progressing measures to protect our communities against the risks posed by extreme weather events. We've also continued to make the changes necessary to move forward as a simpler, NEWS RELEASE August 7, 2025 Contact: Mateo Garcia Telephone: (808) 543-7300 Director, Investor Relations E-mail: ir@hei.com HEI REPORTS SECOND QUARTER 2025 RESULTS HONOLULU - Hawaiian Electric Industries, Inc. (NYSE - HE) (HEI) today ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 28, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35368 CAPRI HOLDINGS LTD (Exact Name of Registrant as Specified in Its Charter) British Virgin Islands N/A (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to San Francisco, California (Address of principal executive offices) (Zip Code) (855) 456-7634 (Registrant's telephone number, including area code) Commission ...

Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET New Haven, Conn., August 7, 2025 – Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company deve ...